A5039535296- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Cancer Cells and Metastasis
- Cancer Treatment and Pharmacology
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Hypoxia, and Metabolism
- Colorectal and Anal Carcinomas
- Cancer, Stress, Anesthesia, and Immune Response
- RNA modifications and cancer
- Cancer therapeutics and mechanisms
- Drug Transport and Resistance Mechanisms
- Colorectal Cancer Screening and Detection
- Cancer Diagnosis and Treatment
- Wnt/β-catenin signaling in development and cancer
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Gastrointestinal Tumor Research and Treatment
- Immune cells in cancer
Institut de Recherche en Cancérologie de Montpellier
2016-2025
Université de Montpellier
2013-2025
Inserm
2013-2025
Institut Regional du Cancer de Montpellier
2015-2024
CEA Valduc
2014-2024
Centre Hospitalier Universitaire de Montpellier
2013-2023
Gefluc Languedoc Roussillon
2016
The University of Texas MD Anderson Cancer Center
2016
Hôpital Saint Eloi
2011-2013
Circulating tumor cells (CTC) in blood are promising new biomarkers potentially useful for prognostic prediction and monitoring of therapies patients with solid tumors including colon cancer. Moreover, CTC research opens a avenue understanding the biology metastasis However, an in-depth investigation CTCs is hampered by very low number these cells, especially colorectal Thus, establishment cell cultures permanent lines from has become most challenging task over past year. Here, we describe,...
Mitochondria are considered as the power-generating units of cell due to their key role in energy metabolism and signaling. However, mitochondrial components could be found extracellular space, fragments or encapsulated vesicles. In addition, this intact organelle has been recently reported released by platelets exclusively specific conditions. Here, we demonstrate for first time, that blood preparation with resting platelets, contains whole functional mitochondria normal physiological...
Abstract Purpose: Circulating cell-free DNA (ccfDNA) is a valuable source of tumor material obtained from simple blood sampling that enables noninvasive analysis the genome. Our goal was to carry out multiparametric ccfDNA and evaluate its prognostic value by investigating overall survival (OS) 97 metastatic colorectal cancer patients (mCRC). Experimental Design: Qualitative parameters (determination main KRAS exon2 BRAF V600E mutations) quantitative (total concentration, mutant proportion...
The management of patients with colorectal cancer (CRC) and potentially resectable liver metastases (LM) requires quick assessment mutational status response to pre-operative systemic therapy. In a prospective phase II trial (NCT01442935), we investigated the clinical validity circulating tumor cell (CTC) DNA (ctDNA) detection. CRC LM were treated first-line triplet or doublet chemotherapy combined targeted CTC (Cellsearch®) Kirsten RAt Sarcoma (KRAS) ctDNA (droplet digital polymerase chain...
To unequivocally address their unresolved intimate structures in blood, we scrutinized the size distribution of circulating cell-free DNA (cfDNA) using whole-genome sequencing (WGS) from both double- and single-strand library preparations (DSP SSP, n = 7) quantitative PCR (Q-PCR, 116). The profile healthy individuals was remarkably homogenous when DSP or SSP sequencing. CfDNA had a characteristic nucleosome fragmentation pattern. Overall, our data indicate that proportion cfDNA inserted...
Abstract Purpose: Circulating tumor DNA (ctDNA) has been suggested as a major prognostic factor in resected stage-III colon cancer. We analyzed ctDNA of patients randomized the phase III IDEA-France trial. Experimental Design: was tested for WIF1 and NPY by droplet digital PCR with method developed validated colorectal Disease-free survival (DFS) overall (OS) were via multivariable analysis samples sub-groups according to treatment duration (3/6 months) disease stage (high/low-risk III)....
Circulating tumor cells (CTCs) are important clinical indicators for prognosis and treatment efficacy. However, CTC investigation is hampered by their low number, making the establishment of permanent lines very challenging. We derived characterized nine using blood samples from a patient with metastatic colorectal cancer collected before after chemotherapy targeted therapy, during progression. These cell displayed an intermediate epithelial/mesenchymal phenotype, stem-cell like...
Abstract BACKGROUND Unraveling the molecular mechanisms that regulate biology of metastasis-competent circulating tumor cells (CTCs) is urgently needed to understand metastasis formation and relapse. Our group previously established first cell line (CTC-MCC-41) derived from CTCs a patient with colon cancer. METHODS In this study, we analyzed transcriptome CTC-MCC-41 using Human Genome U133 Plus 2.0 microarrays aim unraveling basis their special features (stem properties ability initiate...
Background Immune checkpoint inhibitors (ICIs) are highly effective in patients with microsatellite instability/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC). Response Evaluation Criteria Solid Tumors (RECIST) 1.1 criteria may underestimate response to ICIs due the pseudoprogression phenomenon. The GERCOR NIPICOL phase II study aimed evaluate frequency of pseudoprogressions MSI/dMMR mCRC treated nivolumab and ipilimumab. Methods Patients previously...
(1) Background: Oxaliplatin is among the most neurotoxic anticancer drugs. Little data are available on long-term prevalence and consequences of chemotherapy-induced peripheral neuropathy (CIPN), even though third largest population cancer survivors made up colorectal cancer. (2) Methods: A multicenter, cross-sectional study was conducted in 16 French centers to assess CIPN, as well its (neuropathic pain, anxiety, depression, quality life) during 5 years after end adjuvant oxaliplatin...
We postulate that a significant part of circulating DNA (cirDNA) originates in the degradation neutrophil extracellular traps (NETs). In this study, we examined plasma level two markers NETs (myeloperoxidase (MPO) and elastase (NE)), as well cirDNA levels 219 patients with metastatic colorectal cancer (mCRC), 114 healthy individuals (HI). found mCRC content these analytes was (i) highly correlated, (ii) all statistically different (p < 0.0001) than HI (N = 114). These three may readily...
6014 Background: EGFR is a known oncogenic driver in HNSCC, and the leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) expressed on cancer stem cells, including HNSCC. Petosemtamab human, common light chain, IgG1 bispecific antibody with ADCC-enhanced activity, targeting LGR5. In dose escalation part of phase 1/2 study, recommended 2 (RP2D) was determined to be 1500 mg every weeks (Q2W). Interim data petosemtamab monotherapy at RP2D 2L/3L HNSCC led 37.2% overall response rate...
One randomized phase III trial comparing chemotherapy (CT) with immune checkpoint inhibitors (ICI) has demonstrated significant efficacy of ICI in deficient DNA mismatch repair system/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer. However, few studies have compared CT other advanced dMMR/MSI-H digestive tumors.
PURPOSE The objective of this work was to establish prognostic models in stage III colon cancer (CC) on the basis transcriptomic signatures tumor microenvironment (TME) and cell cycle from PETACC-8 (training set) IDEA-France (validation trials. PATIENTS AND METHODS 3'RNA sequencing performed 1,733 patients trial 1,248 trial. Four were analyzed: T-cell macrophage M2 signatures, expression CXCL13, a score Oncotype DX CC Recurrence Score using same formula stromal score. Immune Proliferative...
Subpopulations of cancer stem-like cells (CSC) are thought to drive tumor progression and posttreatment recurrence in multiple solid tumors. However, the mechanisms that maintain stable proportions self-renewing CSC within heterogeneous tumors under homeostatic conditions remain poorly understood. Progastrin is a secreted peptide exhibits tumor-forming potential colorectal cancer, where it regulates pathways known modulate colon behaviors. In this study, we investigated role progastrin...
Triplet chemotherapy plus cetuximab showed promising results in phase II trials unsystematically selected RAS population. We evaluated FOLFIRINOX+cetuximab efficacy as first-line treatment extended wild-type metastatic colorectal cancer (mCRC) patients.
Background Immune checkpoint inhibitors (ICIs) are recommended to treat patients with deficient mismatch repair/microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC). Pivotal trials have fixed a maximum ICI duration of 2 years, without compelling rationale. A shorter treatment has the potential improve patients' quality life and reduce both toxicity cost compromising efficacy. Here we examine whether early discontinuation (ETD) before 13 months in progressive...
PURPOSE Immunoscore (IS) and circulating tumor DNA (ctDNA) are two emerging technologies in improving prognostication tailoring adjuvant treatments patients resected from a stage III colon cancer (CC). Here, we analyzed the prognostic value of biomarkers who participated randomized phase IDEA-France HORG trials. METHODS Plasma samples were collected after surgery before chemotherapy. ctDNA analysis was performed using clinically validated, personalized, tumor-informed 16-plex protein chain...
Abstract Despite recent advances in the treatment of colorectal cancer (CRC), tumor resistance is a frequent cause chemotherapy failure. Therefore, new options are needed to improve survival patients with irinotecan-refractory CRCs, particularly those bearing KRAS mutations that preclude use anti-EGFR therapies. In this study, we investigated whether sorafenib could reverse irinotecan resistance, thereby enhancing therapeutic efficacy routinely used irinotecan-based chemotherapy. We both...
// Michael J. Overman 1 , Van Morris Helen Moinova 2 Ganiraju Manyam 6 Joe Ensor 3 S. Lee 8 Cathy Eng Bryan Kee David Fogelman Rachna T. Shroff Thomas LaFramboise 4 Thibault Mazard Tian Feng Stanley Hamilton 7 Bradley Broom James Lutterbaugh Jean-Pierre Issa 5 Sanford D. Markowitz and Scott Kopetz Department of Gastrointestinal Medical Oncology, The University Texas M. Anderson Cancer Center, Houston, TX, USA Medicine Case Comprehensive Western Reserve Cleveland, OH, Houston Methodist...
As circulating DNA (cirDNA) is mainly detected as mononucleosome-associated (mono-N cirDNA) in blood, apoptosis has until now been considered the main source of cirDNA. The mechanism cirDNA release into circulation, however, still not fully understood. This work addresses that knowledge gap, working from postulate neutrophil extracellular traps (NET) may be a cirDNA, and by investigating whether NET directly produce mono-N